Cargando…

Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control

Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease accompanied by vascular dysfunction and a tremendous increase in cardiovascular mortality. Numerous adipose-tissue-derived factors and beta cell dysfunction contribute to the increased cardiovascular risk in patients with T2DM. N...

Descripción completa

Detalles Bibliográficos
Autores principales: Forst, Thomas, Weber, Matthias M., Pfützner, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345223/
https://www.ncbi.nlm.nih.gov/pubmed/22577369
http://dx.doi.org/10.1155/2012/635472
_version_ 1782232122286669824
author Forst, Thomas
Weber, Matthias M.
Pfützner, Andreas
author_facet Forst, Thomas
Weber, Matthias M.
Pfützner, Andreas
author_sort Forst, Thomas
collection PubMed
description Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease accompanied by vascular dysfunction and a tremendous increase in cardiovascular mortality. Numerous adipose-tissue-derived factors and beta cell dysfunction contribute to the increased cardiovascular risk in patients with T2DM. Nowadays, numerous pharmacological interventions are available to lower blood glucose levels in patients with type 2 diabetes. Beside more or less comparable glucose lowering efficacy, some of them have shown limited or probably even unfavorable effects on the cardiovascular system and overall mortality. Recently, incretin-based therapies (GLP-1 receptor agonists and DPP-IV inhibitors) have been introduced in the treatment of T2DM. Beside the effects of GLP-1 on insulin secretion, glucagon secretion, and gastrointestinal motility, recent studies suggested a couple of direct cardiovascular effects of GLP-1-based therapies. The goal of this paper is to provide an overview about the current knowledge of direct GLP-1 effects on endothelial and vascular function and potential consequences on the cardiovascular outcome in patients with T2DM treated with GLP-1 receptor agonists or DPP-IV inhibitors.
format Online
Article
Text
id pubmed-3345223
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33452232012-05-10 Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control Forst, Thomas Weber, Matthias M. Pfützner, Andreas Exp Diabetes Res Review Article Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease accompanied by vascular dysfunction and a tremendous increase in cardiovascular mortality. Numerous adipose-tissue-derived factors and beta cell dysfunction contribute to the increased cardiovascular risk in patients with T2DM. Nowadays, numerous pharmacological interventions are available to lower blood glucose levels in patients with type 2 diabetes. Beside more or less comparable glucose lowering efficacy, some of them have shown limited or probably even unfavorable effects on the cardiovascular system and overall mortality. Recently, incretin-based therapies (GLP-1 receptor agonists and DPP-IV inhibitors) have been introduced in the treatment of T2DM. Beside the effects of GLP-1 on insulin secretion, glucagon secretion, and gastrointestinal motility, recent studies suggested a couple of direct cardiovascular effects of GLP-1-based therapies. The goal of this paper is to provide an overview about the current knowledge of direct GLP-1 effects on endothelial and vascular function and potential consequences on the cardiovascular outcome in patients with T2DM treated with GLP-1 receptor agonists or DPP-IV inhibitors. Hindawi Publishing Corporation 2012 2012-04-17 /pmc/articles/PMC3345223/ /pubmed/22577369 http://dx.doi.org/10.1155/2012/635472 Text en Copyright © 2012 Thomas Forst et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Forst, Thomas
Weber, Matthias M.
Pfützner, Andreas
Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
title Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
title_full Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
title_fullStr Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
title_full_unstemmed Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
title_short Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
title_sort cardiovascular benefits of glp-1-basedtherapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345223/
https://www.ncbi.nlm.nih.gov/pubmed/22577369
http://dx.doi.org/10.1155/2012/635472
work_keys_str_mv AT forstthomas cardiovascularbenefitsofglp1basedtherapiesinpatientswithdiabetesmellitustype2effectsonendothelialandvasculardysfunctionbeyondglycemiccontrol
AT webermatthiasm cardiovascularbenefitsofglp1basedtherapiesinpatientswithdiabetesmellitustype2effectsonendothelialandvasculardysfunctionbeyondglycemiccontrol
AT pfutznerandreas cardiovascularbenefitsofglp1basedtherapiesinpatientswithdiabetesmellitustype2effectsonendothelialandvasculardysfunctionbeyondglycemiccontrol